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ABSTRACT
Introduction: Teriflunomide, indicated for the
treatment of relapsing–remitting multiple
sclerosis, is contraindicated in pregnancy
based on signs of developmental toxicity in
the offspring of rats and rabbits; developmental
toxicity has also been observed in preclinical
studies of other disease-modifying therapies.
Despite the requirement to use reliable
contraception in clinical trials evaluating the
safety and efficacy of teriflunomide, a number
of pregnancies have been reported. This work
reports pregnancy outcomes in teriflunomide
clinical trials.
Methods: Pregnancy outcomes were evaluated
in a retrospective analysis of the global
pharmacovigilance database. The following
information was collected from the
pharmacovigilance database or individual
patient files: treatment allocation, pregnancy
outcome, teriflunomide exposure, and use of
the accelerated elimination procedure.
Results: At data cut-off, 83 pregnancies were
reported in female patients and 22 pregnancies
were documented in partners of male patients.
All newborns were healthy and did not have
any structural or functional abnormalities at
birth.
Conclusion: Available data do not indicate any
teratogenic signals in patients treated with
teriflunomide.
Keywords: Clinical trials; Multiple sclerosis;
Pregnancy; Teratogenicity; Teriflunomide
INTRODUCTION
In patients with multiple sclerosis (MS),
diagnosis typically occurs during childbearing
years [1, 2]. Consequently, it is important to
understand potential risks during pregnancy
posed by exposure to disease-modifying
therapies (DMTs). MS itself does not appear to
be associated with an increased risk of adverse
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pregnancy outcomes [1]. However, prenatal
exposure to DMTs may adversely impact fetal
development [3].
Teriflunomide is a once-daily, oral
immunomodulator approved for treatment of
relapsing–remitting MS. Teriflunomide is
contraindicated in pregnant women, or
women of childbearing potential not using
reliable contraception, based on the
occurrence of teratogenicity and embryo-
lethality in the offspring of teriflunomide-
treated rats and rabbits [4, 5]. Importantly,
in vitro teriflunomide studies showed no
evidence for mutagenicity, and teriflunomide
was not clastogenic in vivo [4, 5]. Preclinical
studies with other oral DMTs have also shown
potential teratogenic signals in rodents [3].
Reliable contraception should be used
throughout teriflunomide treatment, and
women wishing to become pregnant must
discontinue teriflunomide treatment [4, 5]. In
the event of pregnancy, female patients must
undergo an accelerated elimination procedure
until teriflunomide plasma concentrations fall
below 0.02 mg/L; a level, based on animal
studies, predicted to have minimal risk to the
fetus [4, 5].
Despite the requirement to use reliable
contraception in teriflunomide clinical trials, a
number of pregnancies have been reported. Here,
we present the outcomes of these pregnancies.
METHODS
Pregnancy Monitoring Procedures
Pregnant or lactating females were excluded
from teriflunomide clinical trials. All patients
entering trials were counseled on the potential
risks of drug exposure in pregnancy and
provided written consent not to become
pregnant or to father a child, and to use
reliable contraception. Where pregnancies
were identified, patients were instructed to
discontinue study treatment immediately and
to start an accelerated elimination procedure
[4, 5].
Analysis of Pregnancy Outcomes
A retrospective analysis of the global
pharmacovigilance database was conducted to
evaluate pregnancy outcomes identified in
female study participants and female partners of
male study participants in teriflunomide clinical
trials. The following studies were included:
monotherapy studies Phase 2 proof-of-concept
(NCT01487096) and extension (NCT00228163),
Phase 3 TEMSO (NCT00134563), TEMSO
extension (NCT00803049), TOWER
(NCT00751881), TOPIC (NCT00622700) and
TENERE (NCT00883337); adjunctive therapy
studies Phase 2 interferon beta (NCT00489489),
glatiramer acetate (NCT00475865) and
extensions (NCT00811395), and Phase 3
TERACLES (interferon beta; NCT01252355). The
following information was collected from the
pharmacovigilance database or individual
patient files: treatment allocation, pregnancy
outcome, teriflunomide exposure, and use of
the accelerated elimination procedure.
Compliance with Ethics Guidelines
The data in this article are based on previously
conducted studies, and do not involve any new
studies, with human or animals subjects,
performed by any of the authors.
RESULTS
At data cut-off, 83 pregnancies were reported in
female patients enrolled into teriflunomide
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clinical trials (Table 1). Of these, 13 pregnancies
occurred in women exposed to interferon beta
or placebo. Seventy pregnancies (including one
twin pregnancy) were reported in women with
known teriflunomide exposure; outcomes
included 26 live births, 13 spontaneous
abortions, and 29 induced abortions, including
one abortion of two embryos. Subsequent to the
last data cut-off, one ongoing pregnancy
(Table 1) resulted in the delivery of a baby boy
at 39 weeks of pregnancy. Maternal exposure in
our analysis ranged from 12 days to
approximately 4.5 years. The use of an
accelerated elimination procedure with
cholestyramine (8 or 4 g every 8 h) or
activated charcoal (50 g every 12 h), both of
which have been shown to decrease
teriflunomide concentrations by C98% after
11 days of administration [4, 5] (Fig. 1), was
also documented. Of the 26 pregnancies
exposed to teriflunomide that resulted in live
births, 10 patients discontinued teriflunomide
treatment and nine completed the accelerated
elimination procedure before becoming aware
of their pregnancy. The remaining 16 patients
discontinued teriflunomide treatment a few
days to 11 weeks after becoming pregnant, and
13 of these underwent the accelerated
elimination procedure. The use of the
accelerated elimination procedure in the vast
majority of patients exposed to teriflunomide
minimized exposure to the developing fetus by
rapidly reducing teriflunomide plasma levels
below those predicted to have any fetal risk
(\0.02 mg/L) [4, 5]. Median birth weight,
documented for 18 newborns, was 3.3 kg, and
mean gestational age, documented in 23 cases,
was 39 weeks (range 36–44 weeks). All newborns
were healthy and did not have any structural or
functional abnormalities at birth. The
spontaneous abortion rate in teriflunomide-
exposed patients was 18.6%, within the range
reported for the general population [6]. None of
the induced abortions were performed due to
defects or malformations.
Additionally, 22 pregnancies were
documented in partners of male patients in
the teriflunomide clinical program (Table 1). Of
these, three pregnancies occurred in women
whose partners were exposed to placebo. Of the
19 pregnancies with known paternal
teriflunomide exposure, outcomes included 16
live births, one spontaneous abortion, and two
induced abortions. No structural defects or
functional abnormalities were reported in
newborns with paternal teriflunomide
exposure, and there were no reports of
embryo–fetal abnormalities in either of the
induced abortions.
DISCUSSION
Preclinical studies of some oral DMTs have
shown signals for some developmental toxicity
in rodents [3]. Limited data on clinical
Table 1 Pregnancy outcomes among female patients and








Live birth 26 2 2 30
Induced abortion 29 8 0 37
Spontaneous
abortion
13 1 0 14
Ongoing pregnancy 1a 0 0 1a
Unknown 1 0 0 1
Total 70 11 2 83
Female partners of male patients
Live birth 16 2 – 18
Induced abortion 2 1 – 3
Spontaneous
abortion
1 0 – 1
Total 19 3 – 22
a Following data cut-off, the ongoing pregnancy resulted in the delivery of
a baby boy at 39 weeks of pregnancy
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outcomes of pregnancies associated with DMT
exposure have also been reported in the
literature [3, 7]. Findings from the
teriflunomide clinical development program
have thus far demonstrated no pregnancy
safety concerns. All newborns with prenatal
teriflunomide exposure were healthy and had
no structural defects or functional deficits at
birth. Teriflunomide treatment was not
associated with a higher rate of spontaneous
abortion (18.6%) compared with rates,
including early pregnancy losses, reported in
the general population (17–22%) [6]. These
observations are supported further by evidence
from prospective studies of the parent
compound, leflunomide, approved for the
treatment of rheumatoid arthritis (RA) since
1998 [8]. In a prospective study by the
Organization of Teratology Information
Specialists (OTIS), there were no significant
differences in the rate of major structural
defects, and no specific pattern of major or
minor anomalies, in newborns of women with
RA exposed to leflunomide relative to disease-
matched or healthy comparator groups, with a
similar rate to that in the general population
[9]. This lack of a signal for teratogenicity was
confirmed in a subsequent OTIS analysis [10]. In
addition, leflunomide postmarketing
surveillance of more than 2.4 million patient-
years of exposure has not shown any
teratogenic signal.
Teriflunomide has been detected at low
levels in human semen [4]. However, animal
studies show no evidence that teriflunomide
adversely affects male fertility or damages sperm
DNA [4, 5]. Although animal studies to evaluate
the risk of male-mediated fetal toxicity have not
been conducted, the risk of male-mediated
embryo–fetal toxicity from teriflunomide
treatment is considered low, with estimated
plasma exposure in females from semen transfer
from a male-treated patient expected to be C100
times lower than plasma exposure following
oral dosing of teriflunomide 14 mg [5].
However, to minimize any potential risk, some
regulatory authorities recommend that men
wishing to father a child should also
discontinue teriflunomide treatment and
undergo the accelerated elimination procedure
[4]; no such recommendation is made in the
European labeling for teriflunomide [5].
It is important to collect as much data as
possible to determine potential adverse
outcomes following DMT exposure during
pregnancy. In this regard, global pregnancy
registries for teriflunomide will capture
prospective data from pregnancies that occur
worldwide in the postmarketing setting. In
North America, the independent OTIS group
has established a pregnancy registry to collect
prospective data for women exposed to
teriflunomide during pregnancy [11]. A second
registry will collect pregnancy data from
patients in Europe and Australia.
Fig. 1 Teriﬂunomide plasma concentrations following an
accelerated elimination procedure. A loading dose of
teriﬂunomide (70 mg/day for 3–4 days) was administered
to achieve steady state rapidly; this was followed by a
maintenance dose of teriﬂunomide 14 mg/day for
8–11 days. Cholestyramine [8 or 4 g, three times daily
(tid)] or activated charcoal [50 g, two times daily (bid)]
was administered orally for 11 days following teriﬂuno-
mide treatment. Adapted with permission from Freedman
[14]
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CONCLUSION
While this investigation was not powered to
detect teratogenicity, available data do not
indicate any teratogenic signals in patients
treated with teriflunomide. Teriflunomide has
been shown to be an effective therapeutic
option for patients with MS [12, 13], including
women of childbearing potential using effective
contraception.
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